Investor Presentaiton
CVD - key take aways
R&D investor presentation
Large unmet need in CVD with 510 million patients and 18 million
annual deaths
Aspiration to have at least one product launched between 2024-
2028 targeting ASCVD or HF
Completed acquisition of mid-stage compound, Ziltivekimab,
targeting ASCVD with CKD and inflammation is a key step in
delivering on Novo Nordisk CVD ambition
Ziltivekimab is a fully human ligand monoclonal antibody with
potential for optimised efficacy and safety profile and thereby
potential to become first-in-class and best-in-class product in a
patient population with limited treatments options available
CVD: cardiovascular disease; ASCVD: atherosclerotic cardiovascular disease; HF: heart failure; CKD: chronic kidney diseaseView entire presentation